{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:47:56Z","timestamp":1785041276487,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218408","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:42:12Z","timestamp":1772671332000},"page":"218408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["tRF-1432 orchestrates RBMS1\u2013IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer"],"prefix":"10.1016","volume":"646","author":[{"given":"Yuhan","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangdong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canlet.2026.218408_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.canlet.2026.218408_bib2","first-page":"171","article-title":"Breast cancer treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am. Fam. Physician"},{"issue":"12","key":"10.1016\/j.canlet.2026.218408_bib3","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/cancers11121822","article-title":"Immunotherapy: a challenge of breast cancer treatment","volume":"11","author":"Garc\u00eda-Aranda","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.canlet.2026.218408_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218408_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.canlet.2026.218408_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218408_bib7","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ped.13859","article-title":"Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children","volume":"61","author":"Nishikawa","year":"2019","journal-title":"Pediatr. Int."},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nsmb.3216","article-title":"Mechanistic diversity in ATP-binding cassette (ABC) transporters","volume":"23","author":"Locher","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"70","key":"10.1016\/j.canlet.2026.218408_bib10","doi-asserted-by":"crossref","first-page":"114756","DOI":"10.18632\/oncotarget.21801","article-title":"Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer","volume":"8","author":"Nascimento","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.canlet.2026.218408_bib11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/FTD.0000000000000536","article-title":"A common mdr1 gene polymorphism is associated with changes in linezolid clearance","volume":"40","author":"Allegra","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.molcel.2016.08.009","article-title":"The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through twist activation","volume":"63","author":"Lee","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218408_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.canlet.2026.218408_bib14","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1101\/gad.1837609","article-title":"A novel class of small RNAs: tRNA-derived RNA fragments (tRFs)","volume":"23","author":"Lee","year":"2009","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.canlet.2026.218408_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00109-018-1693-y","article-title":"Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases","volume":"96","author":"Shen","year":"2018","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-023-01739-5","article-title":"Emerging roles of tRNA-derived fragments in cancer","volume":"22","author":"Fu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib17","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s00018-020-03720-7","article-title":"tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation","volume":"78","author":"Krishna","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12079-022-00690-2","article-title":"tRNA-derived fragments (tRFs) in cancer","volume":"17","author":"Pekarsky","year":"2023","journal-title":"J. Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218408_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.03.012","article-title":"tRNA-derived fragments and tRNA halves: the new players in cancers","volume":"452","author":"Zhu","year":"2019","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib20","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1002\/jcp.27533","article-title":"Hypoxia-induced tRNA-derived fragments, novel regulatory factor for adriamycin resistance in triple-negative breast cancer","volume":"234","author":"Cui","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218408_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cell.2015.02.053","article-title":"Endogenous tRNA-Derived fragments suppress breast cancer progression via YBX1 displacement","volume":"161","author":"Goodarzi","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2026.218408_bib22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/2159-8290.CD-19-1375","article-title":"RBMS1 suppresses Colon cancer metastasis through targeted stabilization of its mRNA regulon","volume":"10","author":"Yu","year":"2020","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.canlet.2026.218408_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/10985549.2024.2350540","article-title":"Increased ANKRD1 levels in early senescence mediated by RBMS1-Elicited ANKRD1 mRNA stabilization","volume":"44","author":"Shin","year":"2024","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218408_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-022-04747-3","article-title":"RBMS1 promotes gastric cancer metastasis through autocrine IL-6\/JAK2\/STAT3 signaling","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.canlet.2026.218408_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mc.23647","article-title":"Inhibition of the RBMS1\/PRNP axis improves ferroptosis resistance-mediated oxaliplatin chemoresistance in colorectal cancer","volume":"63","author":"Xu","year":"2024","journal-title":"Mol. Carcinog."},{"issue":"9","key":"10.1016\/j.canlet.2026.218408_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/2159-8290.CD-20-0993","article-title":"Loss of RNA-binding protein RBMS1 promotes a metastatic transcriptional program in colorectal cancer","volume":"10","author":"Carter","year":"2020","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ymthe.2022.08.006","article-title":"The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.canlet.2026.218408_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152067","article-title":"RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11","volume":"131","author":"Zhang","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.canlet.2026.218408_bib29","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41418-022-01012-0","article-title":"Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer","volume":"29","author":"Zhang","year":"2022","journal-title":"Cell Death Differ."},{"issue":"46","key":"10.1016\/j.canlet.2026.218408_bib30","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1038\/s41388-021-02030-x","article-title":"RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA","volume":"40","author":"Block","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2020.03.011","article-title":"How RNA-binding proteins interact with RNA: molecules and mechanisms","volume":"78","author":"Corley","year":"2020","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-024-04934-0","article-title":"Wnt\/\u03b2-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41598-024-85094-5","article-title":"Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer","volume":"15","author":"da Silva Fernandes","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/10717544.2022.2063454","article-title":"A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer","volume":"29","author":"He","year":"2022","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.canlet.2026.218408_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1139\/o05-173","article-title":"ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2","volume":"84","author":"Hong","year":"2006","journal-title":"Biochem. Cell. Biol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218408_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231832","article-title":"IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation","volume":"221","author":"Hsu","year":"2024","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115116","article-title":"IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth","volume":"44","author":"Zhou","year":"2025","journal-title":"Cell Rep."},{"issue":"2-3","key":"10.1016\/j.canlet.2026.218408_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1016\/j.canlet.2026.218408_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.canlet.2026.218408_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","article-title":"Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial","volume":"175","author":"Ravani","year":"2021","journal-title":"JAMA Pediatr."},{"issue":"23","key":"10.1016\/j.canlet.2026.218408_bib41","first-page":"2201","article-title":"Mycophenolate mofetil for immune thrombocytopenia. Reply","volume":"385","author":"Bradbury","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218408_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217823","article-title":"Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer","volume":"627","author":"Wu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218408_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101126","article-title":"crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug Resist. Updates"},{"issue":"4","key":"10.1016\/j.canlet.2026.218408_bib44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11427-023-2491-7","article-title":"The burgeoning importance of PIWI-interacting RNAs in cancer progression","volume":"67","author":"Deng","year":"2024","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218408_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:08:10Z","timestamp":1777550890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"alternative-id":["S0304383526001710"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218408","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"tRF-1432 orchestrates RBMS1\u2013IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218408"}}